Recombinant Human ibpA protein

The IbpA (Iron-regulated Bordetella pertussis autotransporter) recombinant protein is derived from the pathogenic bacterium *Bordetella pertussis*, the causative agent of whooping cough. Autotransporter proteins, a class of virulence factors in Gram-negative bacteria, are characterized by their ability to self-transport across the bacterial outer membrane. IbpA is notably expressed under iron-limiting conditions, a common stress encountered during host infection, suggesting its role in iron acquisition or immune evasion. The protein features a conserved C-terminal β-barrel domain that facilitates autotransport and an N-terminal passenger domain responsible for host-pathogen interactions.

Recombinant IbpA is engineered for heterologous expression, typically in *E. coli*, to study its structural and functional properties without handling the pathogen itself. Its iron-regulated expression hints at involvement in bacterial survival mechanisms, potentially aiding adhesion to host cells or countering iron-sequestering host defenses like lactoferrin. Studies also suggest IbpA may contribute to biofilm formation, enhancing bacterial persistence in the respiratory tract.

Research on IbpA recombinant protein focuses on its application in vaccine development, as it elicits immune responses in animal models. Its immunogenicity and surface exposure make it a candidate for subunit vaccines or diagnostic tools. Additionally, studying IbpA’s interactions with host cells provides insights into *B. pertussis* pathogenesis and potential therapeutic targets. Recombinant technology enables scalable production, high purity, and site-specific modifications for functional studies, accelerating both basic research and translational applications.